SpaCapsule Is Effective In Cellulite-Reduction, Other Aesthetic and Medical Benefits
(EMAILWIRE.COM, November 23, 2010 ) New York, NY - Simulated Environment Concepts (Pink Sheets:SMEV), the manufacturer and developer of medical, aesthetic and wellness equipment, today announced the results of the Body Slimming Study conducted by the DERMSCAN Group. The study proved that continuous use of the SpaCapsule is effective in the reduction of cellulite and offers other aesthetic benefits.
As previously stated, the SpaCapsule was also designed to aid in weight-loss and cellulite treatment, stated Dr. Ella Frenkel, Chairman and CEO of Simulated Environment Concepts, Inc. However, the study has proven results beyond our expectations.
The study, completed October 1st, 2010, is solely based on time spent in the capsule without any external considerations like diet or exercise. Focused on twenty, 30-minute sessions, the results proved significant weight loss in 87% of subjects and a noticeable decrease in circumference around the stomach and hips (the areas of study). Aesthetic benefits included improvements in skin elasticity in 80% of women with 94% of all subjects demonstrating an overall improvement in skin texture.
These types of results with no other variables; no lotions, no diets, no exercising regiments, etc., is truly incredible, stated Dr. Ilya Spivak, Marketing Director and Co-Inventor of the SpaCapsule. Of course, the proper diet, exercise, and vitamin supplementation is essential for weight loss, health and daily living. However, this study supports that these same initiatives can be greatly enhanced by simply enjoying 30-minute treatments in the SpaCapsule.
With great emphasis on weight loss, cellulite reduction and therapeutic use throughout Europe, results from this study have already increased international appeal and sales.
Dermscan closely cooperates and has relations with French (AFSSAPS, DGCCRF, DGS, etc.) and international (FDA, KFA, COLIPA, etc.) regulatory bodies. Member of the European Commission, SFC, NIPHAR, COVREC, ACIDIM, UNITIS, and many others. The company is licensed by French Government to conduct studies and clinical trials. It is authorized as site for biomedical research on human subjects by the AFSSAPS (the French FDA equivalent) and the French Ministry of Health (#22016 MHC and S).
About Simulated Environment Concepts, Inc.
Simulated Environment Concepts, Inc. (SE Concepts) (SYMBOL: SMEV) is an industry leading manufacturer and developer of cutting edge medical, health and wellness equipment.
SE Concepts was established in 2000 by doctors dedicated to advancements in medical technology and aesthetics. Its flagship product, SpaCapsule, which is currently distributed in over 37 countries, is a robotic massage therapy system used for medical rehabilitation, relaxation, weight loss, cellulite management and general wellness.
Statements in this news release that are not historical facts, including statements about plans and expectations regarding products and opportunities, demand and acceptance of new or existing products, capital resources and future financial results are forward-looking. Forward-looking statements involve risks and uncertainties which may cause the Company's actual results in future periods to differ materially from those expressed. These uncertainties and risks include changing consumer preferences, lack of success of new products, loss of the Company's customers, competition and other factors discussed from time to time in the Company's filings with the Securities and Exchange Commission.
SpaCapsule is registered trademark of Simulated Environment Concepts, Inc.
Other stocks to keep an eye on for Tuesday's trading session include:
Altair Nanotechnologies, Inc. (NASDAQ: ALTI), Quantum Fuel Systems Technologies Worldwide, Inc. (Nasdaq: QTWW), Oracle (NASDAQ: ORCL), Apple Inc. (NASDAQ: AAPL), Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX).
Disclosure: All material herein was prepared by Keros Capital Inc. (Keros) based upon information believed to be reliable. The information contained herein is not guaranteed by Keros to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Keros is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.keroscapital.com or mentioned herein. Keros has been compensated two million shares for coverage of SMEV. Keros affiliates, officers, directors and employees may own shares and may buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. Keros will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. Copyright 2007 by Keros Capital. All rights reserved. This publication or part thereof may not be duplicated or reprinted without the written permission of the Publisher. Facsimile including photocopy(s) is strictly forbidden, except for facsimile correspondence between Keros Capital. If this publication contravenes any securities laws and/or regulations, the securities regulations of the country will prevail. In this event, this publication must be discarded immediately.